Prasugrel

Prasugrel (marketing name Effient in the US, Efient in the EU and Prasita in India) is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the US Food and Drug Administration approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI.

Properties:

Appearance & Physical State: White solid

Density: 1.347

Boiling Point: 493.5ºC at 760 mmHg

Flash Point: 252.3ºC

Refractive Index: 1.619

Vapor Pressure: 0mmHg at 25°C

P2 Receptor Inhibitors Related Products:

Prasugrel metabolite; MRS 2578; Ticagrelor; A-740003; Clopidogrel sulfate; Ivermectin (MK-933); Minodronic acid; AF-353

[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46.

[2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami

[3]. Darius H. Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90.